Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study
Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment. To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD. A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, pl...
Gespeichert in:
| Veröffentlicht in: | British journal of psychiatry 2001-07, Vol.179 (1), p.15-22 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 22 |
|---|---|
| container_issue | 1 |
| container_start_page | 15 |
| container_title | British journal of psychiatry |
| container_volume | 179 |
| creator | ALLGULANDER, CHRISTER HACKETT, DAVID SALINAS, ELISEO |
| description | Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment.
To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD.
A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER.
All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups.
Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months. |
| doi_str_mv | 10.1192/bjp.179.1.15 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_597465</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71011033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c335t-a29b3f544e793b6ee231a2b86c7a6e2d3602e8360dbf6854363352fc3c2f82c93</originalsourceid><addsrcrecordid>eNpdkV1rFDEUhoNY7Lp657UEBFEwaz4m8-GdlFYLhYJUb0Mmc2Y329lkTDLszl_wVzdlFwu9yRfPec_J-yL0jtEVYw3_2m7HFauaFVsx-QItWFFxwopSvkQLSmlFGJf0HL2OcZuvouDVK3TOWCEkL8UC_fsDbtC9PlgHGA4JXAcdDjCAjoA_Xf76jK3DaQM4BdBpBy5h3-M1OAh6sDHD2h0spBl3NvrQQfiG7_YZm0nvp0D2APd4HLSB1hPjXQp-GHJV5yOQoN3aujWOaermN-is10OEt6d9iX5fXd5d_CQ3tz-uL77fECOETETzphW9LAqoGtGWAFwwzdu6NJUugXeipBzqvHZtX9ayEGUu470Rhvc1N41YInLUjXsYp1aNwe50mJXXVp2e7vMJlGyq7GPmPx75Mfi_E8SkdjYaGAbtwE9RVYwyRoXI4Idn4DY74PJfVJ5Rylo02fMl-nKkTPAxBuj_D8CoekxU5URVTlQxxR67vz-JTu0Ouif4FGEG8BHY2PVmbwOoYMY4m82TxgNGIKko</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2315583926</pqid></control><display><type>article</type><title>Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Cambridge University Press Journals Complete</source><creator>ALLGULANDER, CHRISTER ; HACKETT, DAVID ; SALINAS, ELISEO</creator><creatorcontrib>ALLGULANDER, CHRISTER ; HACKETT, DAVID ; SALINAS, ELISEO</creatorcontrib><description>Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment.
To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD.
A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER.
All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups.
Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.</description><identifier>ISSN: 0007-1250</identifier><identifier>EISSN: 1472-1465</identifier><identifier>DOI: 10.1192/bjp.179.1.15</identifier><identifier>PMID: 11435263</identifier><language>eng</language><publisher>England: RCP</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antidepressants ; Antidepressive Agents, Second-Generation - administration & dosage ; Anxiety ; Anxiety disorders ; Anxiety Disorders - drug therapy ; Chronic Disease ; College professors ; Comorbidity ; Cyclohexanols - administration & dosage ; Delayed-Action Preparations ; Discontinued ; Dosage ; Double-Blind Method ; Double-blind studies ; Efficacy ; Family physicians ; Female ; Generalized anxiety disorder ; Humans ; Male ; Mental depression ; Middle Aged ; Psychiatric Status Rating Scales ; Psychiatry ; Release ; Venlafaxine ; Venlafaxine Hydrochloride</subject><ispartof>British journal of psychiatry, 2001-07, Vol.179 (1), p.15-22</ispartof><rights>Copyright © Royal College of Psychiatrists, 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c335t-a29b3f544e793b6ee231a2b86c7a6e2d3602e8360dbf6854363352fc3c2f82c93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,12825,27901,27902,30976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11435263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1946348$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>ALLGULANDER, CHRISTER</creatorcontrib><creatorcontrib>HACKETT, DAVID</creatorcontrib><creatorcontrib>SALINAS, ELISEO</creatorcontrib><title>Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study</title><title>British journal of psychiatry</title><addtitle>Br J Psychiatry</addtitle><description>Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment.
To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD.
A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER.
All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups.
Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antidepressants</subject><subject>Antidepressive Agents, Second-Generation - administration & dosage</subject><subject>Anxiety</subject><subject>Anxiety disorders</subject><subject>Anxiety Disorders - drug therapy</subject><subject>Chronic Disease</subject><subject>College professors</subject><subject>Comorbidity</subject><subject>Cyclohexanols - administration & dosage</subject><subject>Delayed-Action Preparations</subject><subject>Discontinued</subject><subject>Dosage</subject><subject>Double-Blind Method</subject><subject>Double-blind studies</subject><subject>Efficacy</subject><subject>Family physicians</subject><subject>Female</subject><subject>Generalized anxiety disorder</subject><subject>Humans</subject><subject>Male</subject><subject>Mental depression</subject><subject>Middle Aged</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Release</subject><subject>Venlafaxine</subject><subject>Venlafaxine Hydrochloride</subject><issn>0007-1250</issn><issn>1472-1465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkV1rFDEUhoNY7Lp657UEBFEwaz4m8-GdlFYLhYJUb0Mmc2Y329lkTDLszl_wVzdlFwu9yRfPec_J-yL0jtEVYw3_2m7HFauaFVsx-QItWFFxwopSvkQLSmlFGJf0HL2OcZuvouDVK3TOWCEkL8UC_fsDbtC9PlgHGA4JXAcdDjCAjoA_Xf76jK3DaQM4BdBpBy5h3-M1OAh6sDHD2h0spBl3NvrQQfiG7_YZm0nvp0D2APd4HLSB1hPjXQp-GHJV5yOQoN3aujWOaermN-is10OEt6d9iX5fXd5d_CQ3tz-uL77fECOETETzphW9LAqoGtGWAFwwzdu6NJUugXeipBzqvHZtX9ayEGUu470Rhvc1N41YInLUjXsYp1aNwe50mJXXVp2e7vMJlGyq7GPmPx75Mfi_E8SkdjYaGAbtwE9RVYwyRoXI4Idn4DY74PJfVJ5Rylo02fMl-nKkTPAxBuj_D8CoekxU5URVTlQxxR67vz-JTu0Ouif4FGEG8BHY2PVmbwOoYMY4m82TxgNGIKko</recordid><startdate>20010701</startdate><enddate>20010701</enddate><creator>ALLGULANDER, CHRISTER</creator><creator>HACKETT, DAVID</creator><creator>SALINAS, ELISEO</creator><general>RCP</general><general>Cambridge University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7TK</scope><scope>7XB</scope><scope>88G</scope><scope>88J</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HEHIP</scope><scope>M2M</scope><scope>M2O</scope><scope>M2R</scope><scope>M2S</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20010701</creationdate><title>Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study</title><author>ALLGULANDER, CHRISTER ; HACKETT, DAVID ; SALINAS, ELISEO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c335t-a29b3f544e793b6ee231a2b86c7a6e2d3602e8360dbf6854363352fc3c2f82c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antidepressants</topic><topic>Antidepressive Agents, Second-Generation - administration & dosage</topic><topic>Anxiety</topic><topic>Anxiety disorders</topic><topic>Anxiety Disorders - drug therapy</topic><topic>Chronic Disease</topic><topic>College professors</topic><topic>Comorbidity</topic><topic>Cyclohexanols - administration & dosage</topic><topic>Delayed-Action Preparations</topic><topic>Discontinued</topic><topic>Dosage</topic><topic>Double-Blind Method</topic><topic>Double-blind studies</topic><topic>Efficacy</topic><topic>Family physicians</topic><topic>Female</topic><topic>Generalized anxiety disorder</topic><topic>Humans</topic><topic>Male</topic><topic>Mental depression</topic><topic>Middle Aged</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Release</topic><topic>Venlafaxine</topic><topic>Venlafaxine Hydrochloride</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ALLGULANDER, CHRISTER</creatorcontrib><creatorcontrib>HACKETT, DAVID</creatorcontrib><creatorcontrib>SALINAS, ELISEO</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Sociology Collection</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>British journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ALLGULANDER, CHRISTER</au><au>HACKETT, DAVID</au><au>SALINAS, ELISEO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study</atitle><jtitle>British journal of psychiatry</jtitle><addtitle>Br J Psychiatry</addtitle><date>2001-07-01</date><risdate>2001</risdate><volume>179</volume><issue>1</issue><spage>15</spage><epage>22</epage><pages>15-22</pages><issn>0007-1250</issn><eissn>1472-1465</eissn><abstract>Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment.
To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD.
A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER.
All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups.
Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.</abstract><cop>England</cop><pub>RCP</pub><pmid>11435263</pmid><doi>10.1192/bjp.179.1.15</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1250 |
| ispartof | British journal of psychiatry, 2001-07, Vol.179 (1), p.15-22 |
| issn | 0007-1250 1472-1465 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_597465 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Cambridge University Press Journals Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over Antidepressants Antidepressive Agents, Second-Generation - administration & dosage Anxiety Anxiety disorders Anxiety Disorders - drug therapy Chronic Disease College professors Comorbidity Cyclohexanols - administration & dosage Delayed-Action Preparations Discontinued Dosage Double-Blind Method Double-blind studies Efficacy Family physicians Female Generalized anxiety disorder Humans Male Mental depression Middle Aged Psychiatric Status Rating Scales Psychiatry Release Venlafaxine Venlafaxine Hydrochloride |
| title | Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T10%3A22%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Venlafaxine%20extended%20release%20(ER)%20in%20the%20treatment%20of%20generalised%20anxiety%20disorder:%20Twenty-four-week%20placebo-controlled%20dose-ranging%20study&rft.jtitle=British%20journal%20of%20psychiatry&rft.au=ALLGULANDER,%20CHRISTER&rft.date=2001-07-01&rft.volume=179&rft.issue=1&rft.spage=15&rft.epage=22&rft.pages=15-22&rft.issn=0007-1250&rft.eissn=1472-1465&rft_id=info:doi/10.1192/bjp.179.1.15&rft_dat=%3Cproquest_swepu%3E71011033%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2315583926&rft_id=info:pmid/11435263&rfr_iscdi=true |